← SynDRA
TELAGLENASTAT
SynDRA canonical compound SYN0038390 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | GLS |
|---|
| Mechanism of action | glutaminase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- GLS INHIBITOR
- Glutaminase kidney isoform, mitochondrial inhibitor
- glutaminase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- CB-839
- CB 839
- U6CL98GLP4
- WHO 10815
- telaglenastatum
- RefChem:932667
- Telaglenastat [USAN]
- MFCD28167826
- CB839
- Telaglenast at
- C26H24F3N7O3S
- PRAAPINBUWJLGA-UHFFFAOYSA-N
- CB-839(Telaglenastat)
- UNII-U6CL98GLP4
- CB-839(Telaglenastat)?
- TELAGLENASTAT [INN]
- Telaglenastat (USAN/INN)
- TELAGLENASTAT [WHO-DD]
- GTPL9053
- orb1300456
- CB-839 [WHO-DD]
- SCHEMBL14987180
- SCHEMBL29529521
- SCHEMBL30278811
- CHEBI:231605
- BDBM109086
- GLXC-06047
- HMS3741E19
- HMS3873G13
- HMS6018K17
- EX-A1310
- NSC783415
- NSC795998
- NSC798057
- s7655
- AKOS025396175
- CCG-270102
- CS-3393
- NSC-783415
Look up TELAGLENASTAT in the interactive SynDRA portal →